| 引用本文: |
陈梦, 彭坷平, 王佳怡, 杨军辉, 彭书旺.小青龙汤联合孟鲁司特钠对小儿CVA血清免疫因子、炎症因子水平的影响[J].湖南中医药大学学报,2025,45(6):1089-1093[点击复制] |
|
| |
|
|
| 本文已被：浏览 2855次 下载 3940次 |
| 小青龙汤联合孟鲁司特钠对小儿CVA血清免疫因子、炎症因子水平的影响 |
| 陈梦,彭坷平,王佳怡,杨军辉,彭书旺 |
| (湖南中医药大学第一附属医院, 湖南 长沙 410007;湖南中医药大学, 湖南 长沙 410208) |
| 摘要: |
| 目的 观察小青龙汤联合孟鲁司特钠对小儿咳嗽变异性哮喘（CVA）血清免疫因子、炎症因子水平的影响。方法 选择2024年1月至2024年9月湖南中医药大学第一附属医院儿科门诊及住院的CVA外寒里饮证患儿90例，采用随机数字表法分为观察组、对照组，各45例。对照组冲服孟鲁司特钠颗粒4周，观察组在对照组基础上口服小青龙汤2周。比较两组临床疗效及治疗前后中医证候积分、肺功能[呼气高峰流速（PEF）、用力肺活量（FVC）、第1秒用力呼气容积（FEV1）]、血清免疫因子[血清免疫球蛋白E（IgE）、可溶性程序性死亡配体-1（sPD-L1）]和血清炎症因子[Toll样受体4（TLR4）、嗜酸性粒细胞（EOS）、白细胞介素-4（IL-4）]水平以及不良反应发生情况。结果 治疗后，观察组总有效率（95.56%）高于对照组（80.00%）（P＜0.05）。与治疗前比较，治疗后两组PFE、FEV1、FVC水平均升高（P＜0.05），且观察组高于对照组（P＜0.05）；两组中医证候积分、总分和IgE、sPD-L1、TLR4、EOS、IL-4含量均降低（P＜0.05），且观察组低于对照组（P＜0.05）。两组患儿不良反应发生率比较，差异无统计学意义（P>.05）。结论 小青龙汤联合孟鲁司特钠可提高小儿CVA临床疗效，改善肺功能，降低血清炎症因子、免疫因子水平，且较为安全。 |
| 关键词: 小儿咳嗽变异性哮喘 小青龙汤 孟鲁司特钠 免疫球蛋白E 可溶性程序性死亡配体-1 Toll样受体4 白细胞介素-4 |
| DOI：10.3969/j.issn.1674-070X.2025.06.015 |
| 投稿时间：2024-10-23 |
| 基金项目:湖南省教育厅科学研究青年项目（22B0402）。 |
|
| Effects of Xiaoqinglong Decoction combined with montelukast sodium on the serum levels of immune factors and inflammatory factors in children with cough variant asthma |
| CHEN Meng, PENG Keping, WANG Jiayi, YANG Junhui, PENG Shuwang |
| (The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China;Hunan University of Chinese Medicine, Changsha, Hunan 410208, China) |
| Abstract: |
| Objective To observe the effects of Xiaoqinglong Decoction combined with montelukast sodium on serum levels of immune factors and inflammatory factors in children with cough variant asthma (CVA).Methods A total of 90 patients diagnosed with exterior cold with interior fluid retention pattern of CVA were selected from the pediatric outpatient department and inpatient wards at the First Hospital of Hunan University of Chinese Medicine from January 2024 to December 2024. They were divided into an observation group and a control group using a random number table method, with 45 cases in each group. The control group received oral montelukast sodium tablets for 4 weeks, while the observation group was additionally administered Xiaoqinglong Decoction orally for 2 weeks on the basis of the control group's treatment. The clinical efficacy, TCM pattern scores, pulmonary function [peak expiratory flow (PEF), forced vital capacity (FVC), and forced expiratory volume in one second (FEV1)], serum immune factors [immunoglobulin E (IgE) and soluble programmed death ligand-1 (sPD-L1)], serum inflammatory factors [Toll-like receptor 4 (TLR4), eosinophils (EOS), and interleukin-4 (IL-4)], and the incidence of adverse reactions were compared between the two groups before and after treatment.Results After treatment, the total effective rate in the observation group (95.56%) was higher than that in the control group (80.00%) (P<0.05); both groups showed increased PFE, FEV1, and FVC compared with the pre-treatment levels (P<0.05), with the observation group exhibiting higher values than the control group (P<0.05); the scores for each CM pattern item and the total CM pattern scores decreased in both groups (P<0.05), along with reductions in IgE, sPD-L1, TLR4, EOS, and IL-4 levels (P<0.05), with the observation group demonstrating lower values than the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Xiaoqinglong Decoction combined with montelukast sodium can improve the clinical efficacy in children with CVA, enhance pulmonary function, reduce serum inflammatory and immune factor levels, and is relatively safe. |
| Key words: pediatric cough variant asthma Xiaoqinglong Decoction montelukast sodium immunoglobulin E soluble programmed death ligand-1 Toll-like receptor 4 interleukin-4 |
|
二维码（扫一下试试看！） |
|
|
|
|
